2018 ASH Poster – CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broader and Greater Potency Than Ibrutinib Against Primary and Cultured Malignant B Cells Dec 2, 2018
2018 ASH Poster – Concomitant Targeting of FLT3 and BTK with CG-806 Overcomes FLT3-Inhibitor Resistance Through Inhibition of Autophagy Dec 2, 2018
2018 EHA Poster - CG-806, a Non Covalent Pan-FLT3/Pan-BTK Inhibitor, Exhibits Unique Binding to Wild Type and C481S Mutant BTK and Greater Potency Than Ibrutinib Against Malignant B Cells Jun 15, 2018
2018 AACR Poster - APTO-253 is a new addition to the repertoire of drugs that can exploit DNA BRCA1/2 deficiency Apr 17, 2018
2018 AACR Poster - CG’806, a first-in-class pan-FLT3/pan-BTK inhibitor, targets multiple pathways to kill diverse subtypes of acute myeloid leukemia and B-cell malignancy in vitro Apr 15, 2018
2018 AACR Poster - CG’806, a first-in-class pan-FLT3/pan-BTK inhibitor, demonstrates superiority to other FLT3 and BTK inhibitors against primary patient samples Apr 15, 2018
2017 ASH Poster - CG’806, a First-in-Class Pan-FLT3/BTK Inhibitor, Exhibits Potent Growth Inhibition as a Single Agent and in Combination with a BET Bromodomain Inhibitor and a Bcl2 Inhibitor Against AML and CLL Patient Samples Dec 11, 2017
2017 ASH Poster - CG’806, a Novel Pan-FLT3/BTK Multi-Kinase Inhibitor, Induces Cell Cycle Arrest, Apoptosis or Autophagy in AML Cells Depending on FLT3 Mutational Status Dec 11, 2017
2017 ASH Poster - The Pan-FLT3/BTK Multi-Kinase Inhibitor CG’806 Induces AML Killing in FLT-Mutant and Wild Type Cells, and Exerts Synergistic Pro-Apoptotic Effects with Concomitant Targeting of Anti-Apoptotic Bcl-2 and/or Mcl-1 Dec 10, 2017
2017 AACR Hematologic Malignancies Conference - CG’806, a First‐in‐Class FLT3/BTK Inhibitor, Exerts Superior Potency Against AML Cells Harboring FLT3‐ITD, TKD, and Gatekeeper Mutant or Wild‐Type FLT3 May 7, 2017
